Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871706 | 0.91 | TACR1 (0.41) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871281 | 0.88 | TACR1 (0.41) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5201280 | 0.87 | TACR1 (0.41) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL6619909 | 0.86 | HTR1A (0.46) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871549 | 0.85 | HTT (0.39) | HTR1AHTR1DHTR1BHTR1FTACR1 | |
| SCHEMBL4076932 | 0.85 | HTR1A (0.39) | HTR1AHTR1DHTR1BHTR1FOPRL1 | |
| SCHEMBL5871626 | 0.84 | HTT (0.39) | HTR1AHTR1DHTR1BHTR1FTACR1 | |
| SCHEMBL5871563 | 0.84 | HTT (0.39) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871737 | 0.84 | SCD (0.45) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL4073398 | 0.83 | ALDH1A1 (0.39) | HTR1AHTR1DHTR1BHTR1FDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | claimed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | claimed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | claimed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | claimed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | claimed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | claimed |
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1179532-B1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | EISAI R&D MAN CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20050033056-A1 | Hydroxylated indole derivatives and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003059351-A1 | HYDROXYLATED INDOLE DERIVATIVES AND USES THEREOF | EISAI CO., LTD. (JP) | 2003-07-24 | — | — | WO | disclosed |
| US-6573384-B1 | 1,4-substituted cyclic amine compound which is useful as a pharmaceutical, and an intermediate for the process | EISAI CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-1179532-A1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | Eisai Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| JP-2000355591-A | PRODUCTION OF INDOLE DERIVATIVE AND ITS INTERMEDIATE | EISAI CO LTD | 2000-12-26 | — | — | JP | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | SCD 2882/4885HTR1A 17/4885HTR1D 31/4885 |
| US-20080027039-A1 | Method for treating a motor neuron disease | SMN1; SMN2, NLN, SLC18A2 | SCD 983/4885HTR1A 33/4885HTR1D 160/4885 |
| US-20050033056-A1 | Hydroxylated indole derivatives and uses thereof | TPH2, TPH1, HTR6 | SCD 1095/4885HTR1A 10/4885HTR1D 21/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | SCD 3282/4885HTR1A 14/4885HTR1D 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.